Bendectin and birth defects
Subtitle: the challenges of mass toxic substances litigation
By: Michael D. Green.
Publisher: University of Pennsylvania Press
Published: 1996
Place of publication: Philadelphia
Language: eng
Number of pages: 368
Subjects: Products liability -- Drugs -- United States.; Toxic torts -- United States.; Complex litigation -- United States.; Bendectin (Trademark) -- Toxicology.; Abnormalities, Human.
Description: Benedictin was prescribed to more than thirty-five million American women from its introduction in 1956 until 1983, when it was withdrawn from the market. The drug's manufacturer, Merrill Dow Pharmaceuticals, a major U.S. pharmaceutical firm, joined a list of other companies whose product liabilities would result in precedent-setting litigation. Before it was over, the Benedictin litigation would involve 2,000 claimants over a fifteen-year period. Michael D. Green offers a comprehensive overview of the Benedictin case and highlights many of the key issues in mass toxic substances litigation.
Notes: Includes bibliographical references (p. [353]-359) and index.